中山醫學大學機構典藏 CSMUIR:Item 310902500/21597
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 17918/22933 (78%)
造訪人次 : 7430082      線上人數 : 45
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/21597


    題名: PKC delta-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
    作者: Chen, Chia-Hung
    Wang, Bo-Wei
    Hsiao, Yu-Chun
    Wu, Chun-Yi
    Cheng, Fang-Ju
    Hsia, Te-Chun
    Chen, Chih-Yi
    Wang, Yihua
    Weihua, Zhang
    Chou, Ruey-Hwang
    Tang, Chih-Hsin
    Chen, Yun-Ju
    Wei, Ya-Ling
    Hsu, Jennifer L.
    Tu, Chih-Yen
    Hung, Mien-Chie
    Huang, Wei-Chien
    貢獻者: 中山醫學大學;醫研所
    關鍵詞: GROWTH-FACTOR RECEPTOR;TYROSINE KINASE INHIBITOR;BREAST-CANCER CELLS;LUNG-CANCER;GLUCOSE-TRANSPORTER;EARLY;PREDICTION;EXPRESSION;PROTEIN;PHOSPHORYLATION;OVEREXPRESSION
    日期: 2021-07-22
    上傳時間: 2021-08-11T05:58:17Z (UTC)
    出版者: ONCOGENE
    ISSN: 0950-9232
    摘要: The tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been widely used for non-small cell lung cancer (NSCLC) patients, but the development of acquired resistance remains a therapeutic hurdle. The reduction of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs. In this study, the upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with the poorer clinical outcome of the NSCLC patients who received EGFR TKI treatment. Blockade of SGLT1 overcame this resistance in vitro and in vivo by reducing glucose uptake in NSCLC cells. Mechanistically, SGLT1 protein was stabilized through the interaction with PKC delta-phosphorylated (Thr678) EGFR in the TKI-resistant cells. Our findings revealed that PKC delta/EGFR axis-dependent SGLT1 upregulation was a critical mechanism underlying the acquired resistance to EGFR TKIs. We suggest co-targeting PKC delta/SGLT1 as a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.
    URI: https://ir.csmu.edu.tw:8080/handle/310902500/21597
    關聯: Oncogene,volume 40
    顯示於類別:[醫學研究所] 期刊論文

    文件中的檔案:

    沒有與此文件相關的檔案.



    SFX Query

    在CSMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋